Ferrosa Therapeutics is developing a first-in-class bispecific antibody intended to correct cytokine-driven dysregulation of iron homeostasis and restore effective erythropoiesis in anemia of inflammation. The company plans to advance its lead program through antibody generation, bispecific engineering, and in vivo proof-of-concept studies supported by the seed financing. Ferrosa was founded in 2026 in Basel, Switzerland by Forty51 Ventures and named Martin Stern, MD as its CEO. It has assembled external advisors with expertise in antibody development, red blood cell biology, and nephrology to guide preclinical and translational work. Financially, the company is at the preclinical stage and has secured $3.5 million in seed capital from Forty51 Ventures to fund near-term development activities. No revenue, users, or other operating metrics were disclosed in the announcement.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026